Abstract
The effects of valsartan and other nonpeptide angiotensin II type 1 (AT1) receptor blockers on the prejunctional actions of angiotensin II were investigated in the isolated left atria of rat. Norepinephrine stores in rat atria were loaded with [3H]norepinephrine, and neuronal norepinephrine release was deduced from the radioactivity efflux. Angiotensin II (10−9 to 10−6 M) produced concentration-dependent enhancement of the electrical stimulation-induced efflux of [3H]norepinephrine from the preparation. Pretreatment of tissues with valsartan, irbesartan, eprosartan, or losartan (10−8 to 10−6 M) produced concentration-dependent inhibitions of the stimulation-induced efflux of radioactivity observed in the presence of angiotensin II (10−7 M). The AT1 receptor blockers did not decrease the “basal” stimulation-induced overflow of radioactivity but rather selectively inhibited the angiotensin II-mediated augmentation of the response. Regression analyses of the inhibition of the angiotensin II-mediated response by valsartan, irbesartan, eprosartan, and losartan revealed corresponding log IC50values (log M, with 95% confidence intervals) of −7.78 (−8.19, −7.51), −7.65 (−8.02, −7.40), −7.12 (−7.37, −6.86), and −6.75 (−7.00, −6.40), indicating that the IC50 values for valsartan and irbesartan are significantly lower than those for eprosartan and losartan. Thus, valsartan is a potent inhibitor of the prejunctional facilitatory effect of angiotensin II on the release of norepinephrine from peripheral sympathetic nerves. This implies that the therapeutic domain of valsartan may be extended to include pathophysiological conditions such as congestive heart failure wherein prejunctional angiotensin II receptors apparently play a significant role. Whether the high potency of valsartan translates into a significant clinical advantage relative to the other agents tested remains to be ascertained.
Footnotes
-
Send reprint requests to: Suraj S. Shetty, Ph.D., Novartis Institute for Biomedical Research, 130/2215, 564 Morris Ave., Summit, NJ 07901-1027. E-mail: suraj.shetty{at}pharma.novartis.com
- Abbreviations:
- RAS
- renin angiotensin system
- SNS
- sympathetic nervous system
- AT1
- angiotensin II type 1
- Ang II
- angiotensin II
- NE
- norepinephrine
- CHF
- congestive heart failure
- SI
- stimulation-induced
- PSS
- physiological salt solution
- CI
- confidence interval
- FR
- fractional release
- Received December 13, 1999.
- Accepted March 15, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|